New medical marijuana regulations: the coming storm

Srivastava, Anita

doi:10.1503/cmaj.131821

Cited by 7 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Health Canada did not regulate the potency or daily consumption of cannabis, although it did set a possession limit of 150 grams. To fill the regulatory void [7][8][9], each provincial College of Physicians and Surgeons (hereafter, the "Colleges") imposed their own prescribing restrictions. (These Colleges, which are responsible for licensing, disciplining, and regulating physicians, are the provincial equivalents to state medical boards in the United States.)…”

Section: Plos Onementioning

confidence: 99%

Lessons from 20 years of medical cannabis use in Canada

2023

View full text Add to dashboard Cite

Background Canada was one of the first countries to regulate the medical use of cannabis. However, literature on Canada’s medical cannabis program is limited. Methods We use administrative data from the medical cannabis program, and licensed cannabis vendor catalog data to describe a) the participation of patients, physicians, and cannabis vendors in the program from its inception in 1999 to 2021, and b) trends in medical cannabis consumption, prices and potency. We also use national surveys conducted over the last several decades to estimate trends in regular cannabis use (medical or otherwise) and how it changed during the medical cannabis access regimes. Results In 2001, the Canadian government granted access to those with physician-documented evidence of a severe health problem that could not be managed using conventional therapies. Most patients accessed cannabis grown under a personal production license. By 2013, authorized daily cannabis dosages were very high. In 2014, the government, concerned over illegal diversion, required that cannabis be purchased from a licensed commercial grower; personal production was banned. Physicians were given responsibility for authorizing patient access. To fill the regulatory void, the physician regulatory bodies in Canada imposed their own prescribing restrictions. After these changes, the number of physicians who were willing to support patient cannabis use markedly decline but the number of patients participating in the program sharply increased. Medical cannabis use varied by province–rates were generally lower in provinces with stricter regulations on physician cannabis prescribing. Most varieties of cannabis oil available for sale are now high in CBD and low in THC. Dry cannabis varieties, conversely, tend to be high in THC and low in CBD. Inflation adjusted prices of most varieties of medical cannabis have declined over time. We find that rates of daily cannabis use (medical or otherwise) increased markedly after the 2014 policy regime. The fraction of Canadians using cannabis daily increased again after the 2018 legalization of recreational cannabis; at the same time, participation in the medical access program declined. Conclusion The implications for patient health outcomes of changes in the medical cannabis program and legalization of recreational use remains an important area for future research.

show abstract

Section: Plos Onementioning

confidence: 99%

Lessons from 20 years of medical cannabis use in Canada

2023

View full text Add to dashboard Cite

show abstract

“…LPs also face risks related to the health and safety consequences of marijuana, which are still being assessed (Beaulieu, Boulanger, Desroches, and Clark, 2016;Choo and Emery, 2017;Kahan and Srivastava, 2014). To date, there are no specific disclosure requirements that ask LPs to discuss these risks.…”

Section: Legal Health and Safety Risks Associated With Marijuana Opmentioning

confidence: 99%

Smoke and Mirrors? Disclosures in the Marijuana Industry in Canada

Mangen¹,

Paduano²,

Paduano³

et al. 2020

Accounting Perspectives

View full text Add to dashboard Cite

Licensed producers (LPs) of marijuana in Canada are embedded in a highly competitive industry where they raise funds from investors to finance their growth. They face substantial risks from the uncertain legal status of marijuana and from its unsettled health and safety consequences. We argue that this context stands to have implications for the disclosures of firms in the marijuana industry. We rely on a multicase study of three large Canadian LPs to explore their mandatory and voluntary disclosures during the third quarter of 2018. We find that their mandatory interim disclosures are largely consistent with disclosure rules that target marijuana operations. We also find that they make voluntary disclosures relevant for their context (e.g., about risks from legal, health, and safety consequences), and that there is variation in these disclosures. We use our findings as a springboard for discussing the antecedents of mandatory and voluntary disclosures in the marijuana industry (i.e., proprietary costs, investor interest, detection costs of selective disclosures), and their consequence (i.e., lack of comparability). We offer suggestions for future research.

show abstract

“…With the new Marihuana for Medical Purposes Regulations (MMPR), the only legal source of cannabis is designated producers licensed by Health Canada. [11][12][13][14] The Federal Government will once again be updating the MMPR in the coming months.…”

Section: Introductionmentioning

confidence: 99%